308430 — Cellbion Co Balance Sheet
0.000.00%
- KR₩400bn
- KR₩386bn
- KR₩2bn
Annual balance sheet for Cellbion Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 10,747 | 5,412 | 7,370 | 29,259 | 22,708 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 27.4 | 237 | 417 | 497 | 552 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 11,654 | 7,563 | 9,001 | 31,571 | 25,103 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1,366 | 1,603 | 1,420 | 956 | 8,856 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 13,851 | 10,037 | 11,346 | 34,408 | 35,195 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3,635 | 5,277 | 1,537 | 1,067 | 2,262 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 5,378 | 7,299 | 3,848 | 4,833 | 12,408 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| ESOP Debt Guarantee | |||||
| Total Equity | 8,472 | 2,738 | 7,497 | 29,575 | 22,787 |
| Total Liabilities & Shareholders' Equity | 13,851 | 10,037 | 11,346 | 34,408 | 35,195 |
| Total Common Shares Outstanding |